Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
J Am Acad Dermatol ; 85(2): 404-408, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34127306

RESUMO

BACKGROUND: Reviews of malpractice claims in the United States show trends of increasing payments with statistically higher payouts for more debilitating and permanent injuries. OBJECTIVES: To examine lawsuits involving notable associated adverse reactions of isotretinoin. METHODS: Court records of US legal trials from 1985 to 2014 were obtained from a major computerized database: LexisNexis. Data were compiled on the demographics of the defendant and plaintiff, litigation over adverse drug reaction, legal allegations, verdicts, and ruling decisions. RESULTS: Seventy unique cases met inclusion criteria and were selected for review. Forty-four cases cited physicians, and 26 cited a pharmaceutical company. When data from physician and pharmaceutical company litigations were combined, individuals 17 years or younger were more likely to be granted litigation outcomes in their favor compared with adults (P = .0016). Cases alleging failure to monitor were associated with an outcome in favor of the plaintiff (P = .0379). LIMITATIONS: Cases settled or terminated before going to court could not be reviewed. CONCLUSIONS: Familiarity with malpractice trends through precedent-setting cases will increase physician awareness of common pitfalls, potentially mitigating litigation risk and improving patient care.


Assuntos
Fármacos Dermatológicos/efeitos adversos , Isotretinoína/efeitos adversos , Imperícia/estatística & dados numéricos , Administração Oral , Fármacos Dermatológicos/administração & dosagem , Humanos , Isotretinoína/administração & dosagem , Fatores de Tempo , Estados Unidos
2.
Br J Anaesth ; 123(2): e333-e342, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31153631

RESUMO

Until recently, the belief that adequate pain management was not achievable while patients remained on buprenorphine was the impetus for the perioperative discontinuation of buprenorphine. We aimed to use an expert consensus Delphi-based survey technique to 1) specify the need for perioperative guidelines in this context and 2) offer a set of recommendations for the perioperative management of these patients. The major recommendation of this practice advisory is to continue buprenorphine therapy in the perioperative period. It is rarely appropriate to reduce the buprenorphine dose irrespective of indication or formulation. If analgesia is inadequate after optimisation of adjunct analgesic therapies, we recommend initiating a full mu agonist while continuing buprenorphine at some dose. The panel believes that before operation, physicians must distinguish between buprenorphine use for chronic pain (weaning/conversion from long-term high-dose opioids) and opioid use disorder (OUD) as the primary indication for buprenorphine therapy. Patients should ideally be discharged on buprenorphine, although not necessarily at their preoperative dose. Depending on analgesic requirements, they may be discharged on a full mu agonist. Overall, long-term buprenorphine treatment retention and harm reduction must be considered during the perioperative period when OUD is a primary diagnosis. The authors recognise that inter-patient variability will require some individualisation of clinical practice advisories. Clinical practice advisories are largely based on lower classes of evidence (level 4, level 5). Further research is required in order to implement meaningful changes in practitioner behaviour for this patient group.


Assuntos
Buprenorfina/administração & dosagem , Dor Crônica/tratamento farmacológico , Técnica Delphi , Transtornos Relacionados ao Uso de Opioides/prevenção & controle , Assistência Perioperatória/métodos , Guias de Prática Clínica como Assunto , Analgésicos Opioides/administração & dosagem , Humanos , Manejo da Dor/métodos
3.
Ecol Appl ; 27(2): 532-544, 2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-27809401

RESUMO

Detailed understanding of forest disturbance interactions is needed for effective forecasting, modelling, and management. Insect outbreaks are a significant forest disturbance that alters forest structure as well as the distribution and connectivity of combustible fuels at broad spatial scales. The effect of insect outbreaks on fire activity is an important but contentious issue with significant policy consequences. The eastern spruce budworm (Choristoneura fumiferana) is a native defoliating insect in eastern North America whose periodic outbreaks create large patches of dead fir and spruce trees. Of particular concern to fire and forest managers is whether these patches represent an increased fire risk, if so, for how long, and how the relationship between defoliation and fire risk varies through space and time. Previous work suggests a temporary increase in flammability in budworm-killed forests, but regional and seasonal variability in these relationships has not been examined. Using an extensive database on historical lightning-caused fire ignitions and spruce budworm defoliation between 1963 and 2000, we assess the relative importance of cumulative defoliation and fire weather on the probability of ignition in Ontario, Canada. We modeled fire ignition using a generalized additive logistic regression model that accounts for temporal autocorrelation in fire weather. We compared two ecoregions in eastern Ontario (Abitibi Plains) and western Ontario (Lake of the Woods) that differ in terms of climate, geomorphology, and forest composition. We found that defoliation has the potential to both increase and decrease the probability of ignition depending on the time scale, ecoregion, and season examined. Most importantly, we found that lagged spruce budworm defoliation (8-10 yr) increases the risk of fire ignition whereas recent defoliation (1 yr) can decrease this risk. We also found that historical defoliation has a greater influence on ignition risk during the spring than during the summer fire season. Given predicted increases in forest insect activity due to global change, these results represent important information for fire management agencies that can be used to refine existing models of fire risk.


Assuntos
Incêndios , Florestas , Mariposas/fisiologia , Picea/fisiologia , Animais , Conservação dos Recursos Naturais , Herbivoria , Modelos Biológicos , Ontário , Dinâmica Populacional
6.
Drug Alcohol Depend ; 235: 109440, 2022 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-35461084

RESUMO

BACKGROUND: During a COVID-19 outbreak in the congregate shelter system in Halifax, Nova Scotia, Canada, a healthcare team provided an emergency "safe supply" of medications and alcohol to facilitate isolation in COVID-19 hotel shelters for residents who use drugs and/or alcohol. We aimed to evaluate (a) substances and dosages provided, and (b) outcomes of the program. METHODS: We reviewed medical records of all COVID-19 isolation hotel shelter residents during May 2021. The primary outcome was successful completion of 14 days isolation, as directed by public health orders. Adverse events included (a) overdose; (b) intoxication; and (c) diversion, selling, or sharing of medications or alcohol. RESULTS: Seventy-seven isolation hotel residents were assessed (mean age 42 ± 14 years; 24% women). Sixty-two (81%) residents were provided medications, alcohol, or cigarettes. Seventeen residents (22%) received opioid agonist treatment (methadone, buprenorphine, or slow-release oral morphine) and 27 (35%) received hydromorphone. Thirty-one (40%) residents received prescriptions stimulants. Six (8%) residents received benzodiazepines and forty-two (55%) received alcohol. Over 14 days, mean daily dosages increased of hydromorphone (45 ± 32 - 57 ± 42 mg), methylphenidate (51 ± 28 - 77 ± 37 mg), and alcohol (12.3 ± 7.6 - 13.0 ± 6.9 standard drinks). Six residents (8%) left isolation prematurely, but four returned. During 1059 person-days, there were zero overdoses. Documented concerns regarding intoxication occurred six times (0.005 events/person-day) and medication diversion/sharing three times (0.003 events/person-day). CONCLUSIONS: COVID-19 isolation hotel residents participating in an emergency safe supply and managed alcohol program experienced high rates of successful completion of 14 days isolation and low rates of adverse events.


Assuntos
COVID-19 , Overdose de Drogas , Pessoas Mal Alojadas , Adulto , Etanol , Feminino , Habitação , Humanos , Hidromorfona , Masculino , Pessoa de Meia-Idade , SARS-CoV-2
8.
Ecol Appl ; 19(5): 1246-52, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19688931

RESUMO

Forest fires are influenced by weather, fuels, and topography, but the relative influence of these factors may vary in different forest types. Compositional analysis can be used to assess the relative importance of fuels and weather in the boreal forest. Do forest or wild land fires burn more flammable fuels preferentially or, because most large fires burn in extreme weather conditions, do fires burn fuels in the proportions they are available despite differences in flammability? In the Canadian boreal forest, aspen (Populus tremuloides) has been found to burn in less than the proportion in which it is available. We used the province of Ontario's Provincial Fuels Database and fire records provided by the Ontario Ministry of Natural Resources to compare the fuel composition of area burned by 594 large (>40 ha) fires that occurred in Ontario's boreal forest region, a study area some 430,000 km2 in size, between 1996 and 2006 with the fuel composition of the neighborhoods around the fires. We found that, over the range of fire weather conditions in which large fires burned and in a study area with 8% aspen, fires burn fuels in the proportions that they are available, results which are consistent with the dominance of weather in controlling large fires.


Assuntos
Incêndios , Árvores/classificação , Tempo (Meteorologia) , Biomassa , Ontário
9.
Otolaryngol Head Neck Surg ; 151(3): 431-7, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24894421

RESUMO

OBJECTIVES: Many medications have the potential for ototoxicity. To potentiate management of this risk, this study examines malpractice litigation trends of lawsuits involving hearing loss associated with medication use. As experts in hearing loss, it may benefit otolaryngologists to be familiar with this information. STUDY DESIGN: Retrospective review. SETTING: All US civil trials. SUBJECTS AND METHODS: Court records of legal trials from 1987 to 2012 were obtained from 2 major computerized databases. Data were compiled on the demographics of the defendant and plaintiff, use of otolaryngologists as expert witnesses, medication used, legal allegations, verdicts, and judgments. RESULTS: Forty-six unique cases met inclusion criteria and were selected for review. Antibiotics (72%), specifically aminoglycosides (47%), were the most common medications cited as causing hearing loss. Eleven (22%) cases were resolved through a settlement before a verdict was reached. Verdicts in favor of the plaintiffs (37%) were awarded an average of $1,134,242. Pediatric patients were more likely to have outcomes in their favor (P = .03) compared to adults. Of the cases found in favor of the plaintiff, the most common reasons cited were inappropriate medication, dose, or duration (59%); failure to properly monitor (39%); and failure to choose a less toxic medication (18%). CONCLUSIONS: Physicians must be aware of the potential effects of the medications they prescribe. An understanding of potential drug interactions, proper monitoring, and appropriate substitution with less toxic medications are important to improve patient care. Analyzing litigation trends may be used to prevent future lawsuits and improve physician awareness.


Assuntos
Perda Auditiva/induzido quimicamente , Perda Auditiva/epidemiologia , Jurisprudência , Imperícia/estatística & dados numéricos , Erros de Medicação/estatística & dados numéricos , Adolescente , Adulto , Criança , Cisplatino/efeitos adversos , Cisplatino/uso terapêutico , Bases de Dados Factuais , Feminino , Gentamicinas/efeitos adversos , Gentamicinas/uso terapêutico , Humanos , Incidência , Responsabilidade Legal , Masculino , Erros de Medicação/legislação & jurisprudência , Estudos Retrospectivos , Medição de Risco , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA